Seeking Alpha

VABYSMO® (faricimab injection) Now Publicly Funded For Macular Edema Secondary to Retinal Vein Occlusion (RVO) and Pre-Filled Syringe (PFS) in Quebec

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs "This expansion in coverage for people with RVO in ...
Fierce Pharma

As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study

Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...
Nasdaq

New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)

Basel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema ...
Healio

FDA approves Vabysmo prefilled syringe for retinal diseases

Please provide your email address to receive an email when new articles are posted on . The prefilled syringe is indicated for wet age-related macular degeneration, diabetic macular edema and retinal ...
FiercePharma

Amid Eylea clash, Roche's Vabysmo keeps climbing despite a slowdown in its momentum

While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea ...